3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
13
Other
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Other neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Carboplatin
1152
Cisplatin
876
Pemetrexed
834
pembrolizumab
608
Paclitaxel
598
Docetaxel
535
Gemcitabine
424
Radiotherapy
377
Erlotinib Hydrochloride
367
Nivolumab
322
Bevacizumab
322
Etoposide
295
durvalumab
254
Drug Therapy
233
osimertinib
218
atezolizumab
208
Radiosurgery
190
Gefitinib
177
Vinorelbine
145
130-nm albumin-bound paclitaxel
124
Magnetic Resonance Spectroscopy
121
Ipilimumab
118
Cetuximab
113
anlotinib
104
tislelizumab
103
Topotecan
101
Cyclophosphamide
101
Taxes
99
Irinotecan
95
Albumin-Bound Paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
High-Intensity Focused Ultrasound Ablation
×
Thoracic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled